Fruquintinib Maintenance Therapy for Advanced CRC After Adjuvant Chemotherapy: A Study on 2-Year Recurrence and Metastasis Rate
Explore the clinical efficacy and safety of fruquintinib as maintenance therapy in patients with advanced colorectal cancer (CRC) who have achieved no evidence of disease (NED) after completing adjuvant chemotherapy, with the 2-year recurrence and metastasis rate as the primary indicator.
原文地址: https://www.cveoy.top/t/topic/fwxb 著作权归作者所有。请勿转载和采集!